Acorda Therapeutics (ACOR) 25.13 $ACOR Acorda Provides

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acorda Therapeutics (ACOR) 25.13 $ACOR

Acorda Provides Financial and Pipeline Update for Second Quarter 2016
BusinessWire - Thu Jul 28, 5:00AM CDT
--Company Reiterates AMPYRA 2016 Net Sales Guidance and Provides Updates on 2016 R&D and SG&A Guidance
ACOR: 25.13 (-0.15)

ARBITRATORS APPOINTED FOR THE REDEMPTION PROCEEDINGS OF BIOTIE'S MINORITY SHARES
Globe Newswire - Tue Jul 19, 1:01AM CDT
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 19 July 2016, at 9.00 a.m. (EET)
BITI: 25.80 (-0.71), ACOR: 25.13 (-0.15)

Acorda to Host Conference Call to Discuss Second Quarter 2016 on July 28, 2016
BusinessWire - Thu Jul 07, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its second quarter 2016 financial results and pipeline updates on Thursday, July 28 at 8:30 a.m. ET.
ACOR: 25.13 (-0.15)

Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.61 (-0.23), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.99 (-0.08), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.36 (unch), RTRX: 18.17 (+0.24), AVEO: 0.99 (-0.01), SNSS: 0.70 (+0.05), LGND: 138.53 (+3.65), BIND: 0.78 (-0.09), ACOR: 25.13 (-0.15)

Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective
BusinessWire - Mon Jun 13, 8:30AM CDT
Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) ("Biotie" or the "Company" announces that the voluntary delisting of its American Depositary Shares ("ADSs" from the NASDAQ Global Select Market ("Nasdaq US" became effective prior to the opening of trading on 13 June, 2016, following the filing, on 2 June 2016, of an application on Form 25 with the U.S. Securities and Exchange Commission (the "SEC" for notifying the SEC of the delisting of the Company's ADSs from NASDAQ US, as announced on 18 May 2016.
BITI: 25.80 (-0.71), ACOR: 25.13 (-0.15)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 100.25 (+0.83), ALXN: 133.50 (+4.90), AEGR: 1.47 (+0.03), ACOR: 25.13 (-0.15)

Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific Meeting of the American Headache Society
BusinessWire - Thu Jun 09, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced pharmacokinetic (PK) data from a Phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption compared to oral and nasal administration of the same active ingredient in healthy adults. The data on CVT-427, an investigational agent under development for the acute treatment of migraines, will be presented on June 10th, 2016, at the 58th Annual Scientific Meeting of the American Headache Society, in San Diego, CA.
ACOR: 25.13 (-0.15)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), LGND: 138.53 (+3.65), ACOR: 25.13 (-0.15)

Celldex (CLDX) Presents Phase II Melanoma Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:45AM CDT
Celldex Therapeutics (CLDX) announced positive phase II data evaluating CDX-301 and CDX-1401 in patients with malignant melanoma at ASCO.
ANIP: 61.06 (+0.46), CLDX: 4.67 (+0.05), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference
BusinessWire - Tue May 31, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 7 at 2:00pm PT (5:00pm ET).
ACOR: 25.13 (-0.15)

The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 39.03 (-0.08), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15), ALKS: 49.56 (-0.34)

Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 98.20 (+1.20), HZNP: 18.89 (-0.40), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), ACOR: 25.13 (-0.15), BIOD: 0.41 (-0.03), XNPT: 7.07 (+0.05)

Acorda Shelves Development of Epilepsy Treatment, Plumiaz
Arpita Dutt - Zacks Investment Research - Mon May 23, 6:39AM CDT
Acorda's (ACOR) decision to terminate the development of Plumiaz was based on data from ongoing studies.
HSKA: 43.41 (+0.86), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Acorda to Discontinue Development of PLUMIAZ for Treatment of Epilepsy Seizure Clusters
BusinessWire - Fri May 20, 5:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will discontinue development of PLUMIAZ(TM) (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure clusters in people with epilepsy. Data from the ongoing clinical trials do not demonstrate its bioequivalence to Diastat(R) rectal gel, needed to re-file the New Drug Application (NDA) under section 505(b)(2). Specifically, the data demonstrated unexpectedly lower nasal mucosa absorption of diazepam in persons with epilepsy compared to studies in healthy volunteers.
ACOR: 25.13 (-0.15)

Biotie Therapies Corp. to Delist Its American Depositary Shares from the Nasdaq Global Select Market
BusinessWire - Wed May 18, 8:00AM CDT
Biotie Therapies Corp. ("Biotie" today announces that its Board of Directors has resolved to voluntarily delist its American Depositary Shares ("ADSs", each representing 80 Biotie ordinary shares with no nominal value ("Shares", from the NASDAQ Global Select Market ("NASDAQ US".
ACOR: 25.13 (-0.15)

BIOTIE CANCELS ALL TREASURY SHARES HELD BY THE COMPANY
Globe Newswire - Wed May 18, 1:02AM CDT
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 May 2016, at 9.00 a.m. (EET)
BITI: 25.80 (-0.71), ACOR: 25.13 (-0.15)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 138

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 84

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 100

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 162

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 49

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 195

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 103

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 104

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Why Investors Are Making Bold Moves with Dell Technologies

Updated Category News Views 178

Investors Show Confidence in Dell Technologies In recent trading sessions, significant investors have adopted a bullish approach to Dell Technologies (NYSE: DELL). Such movements usually signal investor confidence and the possibility of future price movements. Interestingly, options trading data we've analyzed indicates that this activity stemmed from large transactions,...

Continue Reading
Community Heritage Financial Strengthens Capital Position with Debt Offering

Updated Category News Views 78

Community Heritage Financial Completes Subordinated Debt Offering Community Heritage Financial, Inc. (OTC PK: CMHF), parent company of Middletown Valley Bank, has successfully executed a private placement of subordinated debt, amounting to a substantial $12.1 million. This offering of 6.75% Fixed-to-Floating Rate Subordinated Notes, due 2034, reflects the Company’s...

Continue Reading
Evolent Health Poised for Growth Amid Humana Challenges

Updated Category News Views 185

Understanding Evolent Health's Market Position Recently, analysts at Barclays have reaffirmed their positive outlook on Evolent Health (NYSE: EVH), maintaining an Overweight rating and a price target of $39.00. This confidence comes in light of discussions surrounding the impacts of Humana's recent struggles with Medicare Star ratings. The management team at Evolent,...

Continue Reading
Caracole Teams with Centric PLM for Seamless Growth

Updated Category News Views 31

Revolutionizing the Luxury Furniture Game In the world of luxury furnishings, where every curve and finish sends a message, Caracole is making a bold move to streamline its operations. They're throwing the confetti for Centric PLM, a platform that's set to oust the scattered chaos of spreadsheets and emails. And let me tell you, for any investor eyeing the luxury home...

Continue Reading
RaySearch Laboratories: Exciting Year-End Presentation Ahead

Updated Category News Views 105

Join Us for RaySearch Laboratories' Year-End Report Presentation Analysts, investors, and media representatives are cordially invited to a detailed presentation focused on RaySearch Laboratories' Year-end report for the year 2024. Details of the Presentation Set for February 21, 2025, at 10:00 AM CET, the report will be made accessible to attendees starting at 07:45 AM on...

Continue Reading